XML 144 R129.htm IDEA: XBRL DOCUMENT v3.19.1
Segments of Business - Schedule Of Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2017
Revenues                      
Revenues $ 52,429 $ 56,208 $ 53,075 $ 52,607 $ 51,628 $ 53,617 $ 52,061 $ 51,051 $ 214,319 $ 208,357 $ 198,533
Operating profit                      
Corporate Expenses, Net                 (694) (564) (377)
Loss on Debt Extinguishment                 0 (122) 0
Interest Expense                 (264) (283) (308)
Income from Continuing Operations Before Income Taxes                 610 239 6,891
Depreciation and amortization                      
Total                 949 951 910
Expenditures for long-lived assets                      
Total                 426 405 404
United States                      
Revenues                      
Revenues                 176,296 169,943 164,428
Foreign                      
Revenues                      
Revenues                 38,023 38,414 34,105
Operating Segments                      
Revenues                      
Revenues                 214,319 208,357 198,533
Operating profit                      
Operating income                 1,568 1,208 7,576
Corporate                      
Depreciation and amortization                      
Total                 122 111 110
Expenditures for long-lived assets                      
Total                 75 99 98
U.S. Pharmaceutical and Specialty Solutions | Operating Segments                      
Revenues                      
Revenues                 167,763 162,587 155,236
Operating profit                      
Operating income                 2,697 2,535 2,488
Depreciation and amortization                      
Total                 238 210 235
Expenditures for long-lived assets                      
Total                 88 126 109
European Pharmaceutical Solutions | Operating Segments                      
Revenues                      
Revenues                 27,242 27,320 24,847
Operating profit                      
Operating income                 (1,978) (1,681) 173
Depreciation and amortization                      
Total                 257 296 315
Expenditures for long-lived assets                      
Total                 85 104 125
Medical-Surgical Solutions | Operating Segments                      
Revenues                      
Revenues                 7,618 6,611 6,244
Operating profit                      
Operating income                 455 461 401
Depreciation and amortization                      
Total                 118 97 101
Expenditures for long-lived assets                      
Total                 110 34 9
Other | Operating Segments                      
Revenues                      
Revenues                 11,696 11,839 12,206
Operating profit                      
Operating income                 394 (107) 4,514
Depreciation and amortization                      
Total                 214 237 149
Expenditures for long-lived assets                      
Total                 $ 68 $ 42 $ 63